Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B.
Advisors: Oscar R. Colegio.
Özet:
This study demonstrates how PDVC57 is an effective pre-clinical model to test immunomodulatory medications for cutaneous SCC in immunocompetent C57Bl/6 mice. We demonstrated the first analysis of myeloid populations within the cutaneous SCC tumor microenvironment and found increased Arg1 expression in TAMs. TAM-inhibition using topically delivered Nor-NOHA effectively decreased tumor size and represents a promising new modality to potentially treat cutaneous SCC. Further clinical trials are warranted to test nor-NOHA in patients with cutaneous SCC and to determine if monotherapy or combination with checkpoint inhibition is more effective.